A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy

Abstract

There are substantial cultural differences in how patients with cancer value benefit and improved quality of life. Since the majority of the world's population resides outside North America and Western Europe, there may be a need to re-evaluate perceived levels of patient benefit and measures of quality of life.

Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy

“…Acute nausea and vomiting: refers to nausea or vomiting, occurring within 24 hours of administration of chemotherapeutic drugs, and usually 5 to 6 hours, and could sustain for 18 hours (Jordan et al, 2005). The delayed nausea and vomiting: refers to nausea or vomiting, occurring after 24 hours of administration of chemotherapeutic drugs, and usually 40% -50% of delayed nausea and vomiting occurring within 24 to 48 hours after administration of chemotherapeutic drugs, sometimes sustainable for 5 ~ 7 days (Dranitsaris et al, 2001).…”

Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: A willingness to pay study

“…Only two French-speaking European countries participated, and there are substantial cultural differences across countries; this has been shown, for example, for how patients with cancer estimate the benefits of non-emetic chemotherapy in Canada, Italy, Spain and Greece [26]. Another limitation is that French patients are used to having free healthcare, which undermines the reality of the scenario.…”

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

“…This aspect has been investigated for NK 1 receptor antagonists as a class. Patients from Spain, Canada, Italy, and Greece said they would pay a maximum of $US63, $US46, $US34, and $US8 per day (in 2000 $US), respectively, for a 20% reduction in acute emesis (Dranitsaris et al 2001a). The corresponding values placed on a decrease in delayed emesis of 30% were $US50, $US41, $US31, and $US9 per day for 4 days.…”